Fang Du1, Bofan Hu1, Peng Xu2
1Shaanxi University of Chinese Medicine, Xianyang, China
2Department of Oncology, Shaanxi Provincial Hospital of Chinese Medicine, Xi'an, China
The incidence rate and mortality of non-small cell lung cancer are increasing year by year. Some patients are not sensitive to traditional treatment. Today, with the arrival of the era of immunotherapy, the immunotherapy of non-small cell lung cancer is also progressing and developing. This paper mainly reviews the progress of immunotherapy of non-small cell lung cancer in recent years.
Non-small cell lung cancer; Immunotherapy; Latest progress
Fang Du, Bofan Hu, Peng Xu. Progress in Immunotherapy for Non-small Cell Lung Cancer. Frontiers in Medical Science Research (2022) Vol. 4, Issue 8: 19-23. https://doi.org/10.25236/FMSR.2022.040805.
 Jasmine K, Jackson E, L. MA, et al. Immunotherapy for Non-small Cell Lung Cancer (nsclc), as a Stand-alone and in Combination Therapy [J]. Critical Reviews in Oncology/hematology, 2021 (prepublish).
 Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl [J]. Med. 378, 1976-1986 (2018).
 Zhang Ying, Chen Qian, Shi Yuxia, etc. Application progress of neoadjuvant immunotherapy in non-small cell lung cancer [J]. Anhui Medicine, 2022, 43 (2): 240-243.
 Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838-857 (2021).
 Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer [J]. N Engl J Med. 2022; 10.1056.
 Passiglia F, Bertaglia V, Reale ML, et al. Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon [J]. Cancer Treat Rev. 2021; 101 :102308.
 Bai R, Li L, Chen X, Chen N, Song W, Cui J. Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients with Early-Stage Non-small Cell Lung Cancer [J]. Front Oncol. 2020; 10: 575472. Published 2020 Oct 9.
 Cheng Y, Zhang L, Hu J, et al. Pembrolizumab Plus Chemotherapy for Chinese Patients with Metastatic Squamous NSCLC in KEYNOTE-407 [J]. JTO Clin Res Rep. 2021;2(10):100225. Published 2021 Sep 25.
 Zhou C, Wang Z, Sun Y, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial [J]. Lancet Oncol. 2022; 23(2): 220-233.
 Kuznik A, Smare C, Chen CI, et al. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer with Programmed Death-Ligand 1 Expression ≥50 [J]. Value Health. 2022; 25(2): 203-214.
 Ren S, Chen J, Xu X, et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial [J]. J Thorac Oncol. 2022; 17(4): 544-557.
 O'Byrne KJ, Lee KH, Kim SW, et al. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients [J]. ESMO Open. 2022; 7(1): 100394.
 Reck M, Ciulenua T-E, Cobo M, et al. First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. 2021 ASCO. Abstr 9000.
 Three-Drug Regimen Bests Chemo in NSCLC. Cancer Discov [J]. 2021; 11(11): OF2.
 Hegde, P. S., Wallin, J. J. & Mancao, C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin. Cancer Biol. 52, 11 7-124 (2018).
 Oyama, T. et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells [J]. Immunol. 160, 1224-1232 (1998).
 Reck, M. et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med. 7, 387-401(2019)
 Sharma SV, Bell DW, Settleman J, et al. Epidermal grow th factor receptor mutations in lung cancer. Nat Rev Cancer, 2007, 7(3): 169-181.
 West HJ, McCleland M, Cappuzzo F, et al. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. J Immunother Cancer. 2022;10(2): e003027.
 Xue Y, Zheng K, Xue J. Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report. Ann Palliat Med. 2021; 10(9): 10114-10123.
 Xing P, Wang M, Zhao J, et al. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. Thorac Cancer, 2021, 12(20): 2825-2828.
 Jiang T, Wang P, Zhang J, et al. Toripalimab plus chemotherapy as second-line treatment in prev iously EGFR-TK I treated patients w it h EGF R-mut a nt-adv a nced NSC L C: a mu lt icenter pha se-II trial. Signal Transduct Target Ther, 2021, 6(1): 355.
 HSU P C, JABLONS D M, YANG C T, et al. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1(PDL1) in Non-Small CellLung Cancer (NSCLC) [J]. Int J Mol Sci, 2019, 20(15): 3821-3822.
 LIU S Y, WU Y L. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC) [J]. Expert Opin Investig Drugs, 2020, 29(12): 1355-1364.
 Jazieh K, Khorrami M, Saad A, et al. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. J Immunother Cancer. 2022;10(3): e003778.
 Jabbour SK, Lee KH, Frost N, et al. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial [published online ahead of print, 2021 Jun 4]. JAMA Oncol. 2021; 7(9): 1-9.
 Wang N, Zhao L, Zhang D, Jia Y, Kong F. Zhongguo Fei Ai Za Zhi. 2022; 25(3): 214-218. doi: 10.3779/j.issn.1009-3419.2022.102.01.